Platinum(II) complexes of dipyridophenazine as metallointercalators for DNA and potent cytotoxic agents against carcinoma cell lines
Citation
Cm. Che et al., Platinum(II) complexes of dipyridophenazine as metallointercalators for DNA and potent cytotoxic agents against carcinoma cell lines, CHEM-EUR J, 5(11), 1999, pp. 3350-3356
Categorie Soggetti
Chemistry
Journal title
CHEMISTRY-A EUROPEAN JOURNAL
SICI code
0947-6539(199911)5:11<3350:PCODAM>2.0.ZU;2-V
Abstract
The synthesis and spectroscopic characterization of a new class of DNA-inte
rcalating platinum(II) complexes, [Pt(dppz)(tN(Lambda)C)]CF3SO3 (dppz = dip
yrido[3,2-a:2',3'-c]phenazine, tN(Lambda)CH = 4-tert-butyl-2-phenylpyridine
) and [Pt(dppz)(L)(2)](CF3SO3)(2) (L = 1-methylimidazole (Meim-1) or 4-amin
opyridine (NH(2)py-4)) are described. All the complexes are photoluminescen
t in degassed acetonitrile at, room temperature. [Pt(dppz)(tN(Lambda)C)]CF3
SO3 shows a vibronic structured emission (lambda(max) = 477 nm) which is as
signed to the intraligand transition (IL) of the C-deprotonated 4-tert-buty
l-2-phenylpyridine ligand. Both [Pt(dppz)(Meim-1)(2)]-(CF3SO3)(2) and [Pt(d
ppz) (NH(2)py-4)(2)]-(CF3SO3)(2) display a lower energy emission band with
lambda(max) at 558 nm, which is originated from a (MLCT)-M-3 state [5d(Pt)
-->pi*(dppz)]. The binding reactions of platinum(Il) complexes with double-
stranded DNA (dsDNA) were studied by spectroscopic methods and the intrinsi
c binding constants (K) are 1.1 x 10(4)-1.3 x 10(4) dm(3) mol(-1). The resu
lts of gel electrophoresis and UV melting experiments revealed that they in
teract strongly with DNA. In aerated aqueous Tris buffer solution, [Pt(dppz
)(tN(Lambda)C)]CF3SO3 is nonemissive. Upon intercalation of [Pt(dppz)-(tN(L
ambda)C)]CF3SO3 into calf thymus DNA (ctDNA), a low energy emission with la
mbda(max) = 650 nm is developed and this is ascribed to exciplex formation
between the excited state of [Pt(dppz)(tN(Lambda)C)](+) with the DNA base p
airs. The cytotoxicity of [Pt(dppz)(tN(Lambda)C)]CF3SO3 was compared to tha
t of cisplatin using human carcinoma KB-3-1 and its multidrug-resistant sub
clone KB-V1 cell lines, which is 10 and 40 times more potent than cisplatin
in the killing of KB-3-1 and KB-V1 cells. respectively.